How can the CAP /CIP ratio assist in making therapeutic decisions (i.e., dosing of vitamin D, surgery, etc.)?
When “intact” PTH, CAP alone (without the ratio), osteocalcin and the CAP /CIP ratio were compared to bone histology, the CAP /CIP ratio was found to be by far the most useful non invasive predictor of adynamic low bone turnover disease versus normal/high bone turnover disease in patients. (ref. Monier-Faugere, Malluche, et. al., Kidney International, 2001; 60:1460-1468.) Minimally, this basic information gives direction as to when to titrate down suppressive therapy (i.e., vitamin D) due to adynamic low bone turnover disease. Titration details can be derived from package inserts of particular therapeutics.
Related Questions
- Has any other biochemical test been demonstrated to be superior to the CAP /CIP ratio for predicting renal bone disease?
- How can the CAP /CIP ratio assist in making therapeutic decisions (i.e., dosing of vitamin D, surgery, etc.)?
- What happens to the CAP /CIP ratio when the dose of vitamin D or calcium is decreased?
